950 completed, 312 unknown, 239 recruiting, 204 terminated. 1106 Phase 2, 542 Phase 3, 398 Phase 1, 66 Not applicable, 44 Phase 4.
Follow Fluorouracil: new trials by email Literature Review of Fluorouracil trials Research Report on Fluorouracil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 3 | Not yet recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 820 | 2027-06-30 | 2026-09-29 |
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 600 | 2027-02-01 | 2026-09-14 |
| Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma Biospecimen Collection, Echocardiography Test, Fluorouracil - Childhood Posterior Fossa Ependymoma | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 70 | 2026-12-11 | 2026-09-30 |
| Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer Biospecimen Collection, Computed Tomography, Fluorouracil - Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 30 | 2026-12-01 | 2026-09-02 |
| Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer varsetatug masetecan, bevacizumab + 5-FU + leucovorin, bevacizumab - Colo-rectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | CytomX Therapeutics | 368 | 2026-12-01 | 2026-10-28 |
| A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer Zolbetuximab, Oxaliplatin, Folinic Acid - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Phase 4 | Not yet recruiting | Astellas Pharma Global Development, Inc. | 50 | 2026-11-30 | 2026-09-21 |
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
| FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II) Oxaliplatin, 5-Fluorouracil, Levofolinic Acid For Injection - Metastatic Colorectal Cancer (CRC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 229 | 2026-11-01 | 2026-10-16 |
| A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) MK-2010, Pembrolizumab, 5-Fluorouracil - Malignant Neoplam, Advanced Solid Tumors | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 480 | 2026-10-27 | 2026-10-08 |
| SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Northwestern University | 125 | 2026-10-26 | 2026-10-29 |
| TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread TQB2922 injection (subcutaneous administration), Oxaliplatin, Calcium folinate (leucovorin calcium) - Colorectal Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 64 | 2026-10-20 | 2026-09-28 |
| A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) Sac-TMT, Pembrolizumab and Berahyaluronidase alfa, Cisplatin - Bladder Cancer | Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 400 | 2026-10-20 | 2026-09-21 |
| Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) Petosemtamab, Cetuximab, Bevacizumab - Colorectal Cancer | Phase 3 | Recruiting | Genmab | 600 | 2026-10-07 | 2026-10-09 |
| DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2026-10-01 | 2026-10-05 |
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients FOLFIRI+cetuximab, Guardant360 ctDNA assay - Colorectal Cancer Metastatic | Phase 3 | Not yet recruiting | Charite University, Berlin, Germany | 267 | 2026-10-01 | 2026-07-29 |
| Pathological Response to Perioperative FLOT in Gastric Adenocarcinoma FLOT Chemotherapy - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | Fundación Santa Fe de Bogota | 90 | 2026-10-01 | 2026-10-05 | |
| A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation Olomorasib, Cetuximab, Oxaliplatin - Colorectal Neoplasms | Phase 2 | Not yet recruiting | Eli Lilly and Company | 50 | 2026-10-01 | 2026-10-15 |
| A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy Tambotatug pelitecan, Liposomal irinotecan, 5 Fluorouracil - Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 3 | Not yet recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | 320 | 2026-10-01 | 2026-09-04 |
| NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months - Advanced Small Intestine Cancer, Appendiceal Cancers | Phase 1 | Recruiting | The Methodist Hospital Research Institute | 22 | 2026-09-18 | 2026-09-25 |
Showing 20 of 1985. Sign in to see all of them.
Colorectal Neoplasms (503) · Rectal Neoplasms (268) · Colonic Neoplasms (220) · Pancreatic Neoplasms (191) · Stomach Neoplasms (190) · Esophageal Neoplasms (135) · Breast Neoplasms (120) · Neoplasm Metastasis (118) · Squamous Cell Carcinoma of Head and Neck (97) · Neoplasms (94) · Head and Neck Neoplasms (92) · Adenocarcinoma Of Esophagus (73) · Esophageal Squamous Cell Carcinoma (65) · Carcinoma, Hepatocellular (56) · Adenocarcinoma (43)
National Cancer Institute (NCI) (82) · Sun Yat-sen University (61) · M.D. Anderson Cancer Center (39) · Fudan University (35) · Alliance for Clinical Trials in Oncology (32) · European Organisation for Research and Treatment of Cancer - EORTC (31) · Memorial Sloan Kettering Cancer Center (31) · UNICANCER (31) · Hoffmann-La Roche (30) · Merck Sharp & Dohme LLC (29) · Sanofi (29) · AstraZeneca (22) · GERCOR - Multidisciplinary Oncology Cooperative Group (22) · ImmunityBio, Inc. (21) · Eli Lilly and Company (19)
United States (893) · China (390) · France (240) · Germany (198) · Italy (188) · Spain (173) · United Kingdom (165) · Canada (158) · Japan (134) · South Korea (134) · Belgium (118) · Australia (109) · Taiwan (109) · Poland (80) · Brazil (69)
Norman Wolmark, MD (9) · David J. Adelstein, MD (6) · Al B. Benson, MD, FACP (5) · Alfredo Falcone, MD (5) · Howard S. Hochster, MD (5)
PMID 36306483, PMID 31268130, PMID 32816630, PMID 40341124, PMID 21997132, PMID 33356421, PMID 40207789, PMID 33439695, PMID 34037241, PMID 35623069, PMID 37139963, PMID 41252656, PMID 12049862, PMID 12540794, PMID 17960012, PMID 20797891, PMID 21561347, PMID 23265711, PMID 23493136, PMID 24982463, PMID 26187751, PMID 26861604, PMID 27275632, PMID 27722750, PMID 27986363, PMID 28006055, PMID 28237539, PMID 28797458, PMID 29471013, PMID 30293873, PMID 30679026, PMID 31070690, PMID 31378656, PMID 31811950, PMID 32085892, PMID 32418078, PMID 32939319, PMID 33538338, PMID 33684371, PMID 33792646, PMID 34795131, PMID 34905388, PMID 35594613, PMID 36525610, PMID 36572280, PMID 36940261, PMID 37037952, PMID 37699333, PMID 37957132, PMID 38315963
2023 (24), 2017 (19), U10CA032102 (18), 2016 (17), 2018 (16), 2014 (14), 2015 (13), 2025 (13), U10CA031946 (13), U10CA180820 (13), 2019 (10), U10CA021115 (10), P30CA033572 (9), U10CA180868 (9), 2008 (8)